Dr. Bradley M. Block, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Temple University School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 152
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Temple University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
FL license ME-0061495
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
Medical groups
- Block Nation Chase Smolen Family Medicine Inc (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 152
- Services billed
- 2,967
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 489 | 135 |
| Established patient office or other outpatient visit, 40-54 minutes | 303 | 144 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 234 | 105 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 154 | 68 |
| Insertion of needle into vein for collection of blood sample | 146 | 111 |
| Annual alcohol misuse screening, 5 to 15 minutes | 135 | 135 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 130 | 130 |
| Established patient office or other outpatient visit, 30-39 minutes | 126 | 65 |
| Annual depression screening, 5 to 15 minutes | 108 | 108 |
| Administration of influenza virus vaccine | 99 | 98 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 9 payments worth $4,527 in total to this clinician.
| Novo Nordisk Inc | $4,418 |
|---|---|
| Lilly USA, LLC | $39.57 |
| Pfizer Inc. | $26.40 |
| Novartis Pharmaceuticals Corporation | $23.90 |
| Merck Sharp & Dohme LLC | $20.11 |
| Consulting Fee | $4,418 |
|---|---|
| Food and Beverage | $110 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Nov 19, 2025 | Consulting Fee Multiple Therapeutic Areas | $1,628 |
| Novo Nordisk Inc Nov 13, 2025 | Consulting Fee Diabetes | $1,395 |
| Novo Nordisk Inc Nov 12, 2025 | Consulting Fee Diabetes | $1,395 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $463,348 in research payments for these studies, mostly to the institutions running them.
- A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company · Completed · NCT06047548 - A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Sanofi US Services Inc. · Completed · NCT06208306 - A parallel-group treatment, phase 2, double-blind study of once-weekly subcutaneous LY3457263 compared to placebo in participants with type 2 diabetes mellitus on a stable dose of tirzepatide or semaglutide who failed…
Eli Lilly and Company - Study name not reported
Novo Nordisk As - Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Sanofi US Services Inc. · Active, not recruiting · NCT06676319 - A phase 3 randomized doubleblind placebocontrolled study to assess the efficacy and safety of oncedaily oral danuglipron in adults with overweight or obesity and type 2 diabetes
Pfizer Inc. - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04751487
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.